112 related articles for article (PubMed ID: 1720828)
21. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.
Kobrin I; Viskoper RJ; Laszt A; Bock J; Weber C; Charlon V
Am J Hypertens; 1993 May; 6(5 Pt 1):349-56. PubMed ID: 8512659
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
Kleinbloesem CH; Weber C; Fahrner E; Dellenbach M; Welker H; Schröter V; Belz GG
Clin Pharmacol Ther; 1993 May; 53(5):585-92. PubMed ID: 8491068
[TBL] [Abstract][Full Text] [Related]
23. Renin inhibition with A-64662: effect on blood pressure and hormonal response in man.
Bursztyn M; Gavras I; Tifft CP; Bauer JH; Melby JC; Gavras H
J Hypertens Suppl; 1989 Dec; 7(6):S306-7. PubMed ID: 2698944
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.
Ménard J; Boger RS; Moyse DM; Guyene TT; Glassman HN; Kleinert HD
Circulation; 1995 Jan; 91(2):330-8. PubMed ID: 7805235
[TBL] [Abstract][Full Text] [Related]
25. Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients.
Bragat AC; Blumenfeld J; Sealey JE
J Hypertens; 1997 May; 15(5):459-65. PubMed ID: 9169997
[TBL] [Abstract][Full Text] [Related]
26. Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure.
Clozel JP; Véniant MM; Qiu C; Sprecher U; Wolfgang R; Fischli W
J Cardiovasc Pharmacol; 1999 Nov; 34(5):674-82. PubMed ID: 10547083
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.
de Gasparo M; Cumin F; Nussberger J; Guyenne TT; Wood JM; Menard J
Br J Clin Pharmacol; 1989 May; 27(5):587-96. PubMed ID: 2667598
[TBL] [Abstract][Full Text] [Related]
29. Effects of renin inhibition in the conscious primate Macaca fascicularis.
Hui KY; Knight DR; Nussberger J; Hartley LH; Vatner SF; Haber E
Hypertension; 1989 Nov; 14(5):480-7. PubMed ID: 2680962
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin II plays an important role in maintaining blood pressure in postmenopausal women receiving hormone replacement therapy.
Sumino H; Ichikawa S; Miya Y; Sakamaki T; Kurabayashi M
Am J Hypertens; 2005 Oct; 18(10):1340-6. PubMed ID: 16202859
[TBL] [Abstract][Full Text] [Related]
31. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
32. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
Kiowski W; Linder L; Kleinbloesem C; van Brummelen P; Bühler FR
Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
Delacrétaz E; Nussberger J; Biollaz J; Waeber B; Brunner HR
Hypertension; 1995 Jan; 25(1):14-21. PubMed ID: 7843746
[TBL] [Abstract][Full Text] [Related]
34. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition.
Delacrétaz E; Nussberger J; Püchler K; Wood AJ; Robinson PR; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1994 Sep; 24(3):479-85. PubMed ID: 7528305
[TBL] [Abstract][Full Text] [Related]
35. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
37. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
Herlitz H; Palmgren E; Widgren B; Aurell M
Clin Sci (Lond); 2005 Sep; 109(3):311-7. PubMed ID: 15901242
[TBL] [Abstract][Full Text] [Related]
38. Evidence that the renin decrease during hypoxia is adenosine mediated in conscious dogs.
Höhne C; Krebs MO; Boemke W; Arntz E; Kaczmarczyk G
J Appl Physiol (1985); 2001 May; 90(5):1842-8. PubMed ID: 11299275
[TBL] [Abstract][Full Text] [Related]
39. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.
Weber C; Birnböck H; Leube J; Kobrin I; Kleinbloesem CH; Van Brummelen P
Br J Clin Pharmacol; 1993 Dec; 36(6):547-54. PubMed ID: 12959271
[TBL] [Abstract][Full Text] [Related]
40. Gender affects renal vasoconstrictor response to Ang I and Ang II.
Gandhi SK; Gainer J; King D; Brown NJ
Hypertension; 1998 Jan; 31(1):90-6. PubMed ID: 9449397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
